Tenet Healthcare (THC) to Post Q1 Earnings: What's in Store?
Tenet Healthcare Corporation THC
will report first-quarter 2019 results on Apr 29 after market
close. In the last reported quarter, the company delivered a
positive surprise of 112.5%. However, the bottom line plunged 63.6%
year over year, mainly due to weak operating revenues.
Let’s see how things are shaping up prior to this
announcement:
In the to-be-reported quarter, the company’s performance is likely
to suffer a decline in revenues due to reduced admissions,
inpatient and outpatient surgeries, emergency department visits and
total outpatient visits.
Weak performances by its segments, namely Conifer and Hospital
operations plus other segments might also negatively impact its
revenue stream. Conifer’s bottom line is likely to be hurt by
hospital divestitures.
The Zacks Consensus Estimate for the company’s total revenues in
the to-be reported quarter stands at $4.5 billion, indicating 40.6%
fall from the year-ago reported figure.
The Zacks Consensus Estimate for the stock’s earnings is pegged at
30 cents, suggesting 47.4% decrease from the prior-year reported
number. The metric is likely to be affected in the upcoming
quarterly results due to lower revenues.
However, overdependence on debt to fund the growth-related
investments raises the financial risk for Tenet Healthcare.
What the Quantitative Model States
Our proven model does not conclusively show that Tenet Healthcare
is likely to beat on earnings this to-be-reported quarter. This is
because the stock has the right combination of a positive Earnings
ESP and a favorable Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold)
for this to happen, which is not the case here.
Earnings ESP: Tenet Healthcare has an Earnings ESP
of -10.89%. This is because the Most Accurate Estimate is pegged at
27 cents, lower than the Zacks Consensus Estimate of 30 cents. You
can uncover the best stocks to buy or sell before they are reported
with our Earnings ESP Filter.
Tenet Healthcare Corporation Price and EPS Surprise
Tenet Healthcare Corporation Price and EPS Surprise | Tenet Healthcare Corporation Quote
Zacks Rank: Tenet Healthcare
carries a Zacks Rank #2, which increases the predictive power of
ESP. However, the company’s negative ESP in the combination leaves
surprise prediction inconclusive for the stock this reporting
cycle.
We caution against Sell-rated stocks (#4 or 5) going into the
earnings announcement, especially when the company is seeing
negative estimate revisions.
Stocks to Consider
Some stocks worth considering from the medical sector with the
perfect combination of elements to surpass estimates in the next
releases are as follows:
Aduro Biotech, Inc. ADRO is slated to release third-quarter
earnings figures on May 1. This stock has an Earnings ESP of
+82.00% and a Zacks Rank #2. You can see the complete list
of today’s Zacks #1 Rank stocks here.
bluebird bio, Inc. BLUE has an Earnings ESP of +12.12%. This #3
Ranked company is set to report third-quarter earnings on May
1.
Humana Inc. HUM is set to report first-quarter 2018 earnings
performance on May 1. The stock has an Earnings ESP of +0.84% and a
Zacks Rank of 3.
Radical New Technology Creates $12.3 Trillion Opportunity
Imagine buying Microsoft stock in the early days
of personal computers… or Motorola after it released the world’s
first cell phone. These technologies changed our lives and created
massive profits for investors.
Today, we’re on the brink of the next quantum leap in technology. 7
innovative companies are leading this “4th Industrial Revolution†-
and early investors stand to earn the biggest profits.
See the 7 breakthrough stocks now>>
Want the latest recommendations from Zacks Investment Research?
Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free
report
bluebird bio, Inc. (BLUE) :
Free Stock Analysis Report
Aduro Biotech, Inc. (ADRO)
: Free Stock Analysis Report
Humana Inc. (HUM) : Free
Stock Analysis Report
Tenet Healthcare
Corporation (THC) : Free Stock Analysis Report
To read this article on
Zacks.com click here.
Zacks Investment Research